Irina Elena Haivas
Associate @ Creative Destruction Lab
Irina Elena Haivas is a Series A investor at Creative Destruction Lab focused on Health Care and Software. Irina Haivas is a Principal. Based in London, she works on sourcing and due diligence of global investment opportunities.Irina focuses on businesses that use advanced technologies such as machine intelligence or robotics and automation, to transform large industries. She also focuses on the intersection of science and technology, including nextgeneration biology, as well as on companies in healthcare.Before joining Atomico, Irina was a growth and PE investor at GHO Capital Partners, where she invested, among others, in enterprise software and AI/ML businesses and focused on the intersection of science, healthcare and technology. Before that, Irina was part of the leadership team of Bain & Co. in Europe and the U.S., where she worked directly both with private equity firms on investment diligence, as well as with corporates on Innovation and Product, Go-to-Market, BD and acquisitions, and organisation scale-up. While at Bain she seconded in an operational role at Medtronic, one of the world’s largest medical engineering companies.Irina is a former surgeon, having studied medicine at Freiburg University in Germany and Iasi Medical University in Romania. She was a surgical fellow at Harvard Medical School before completing an MSc (Dist) in International Health Policy at London School of Economics.Irina speaks Romanian, English, advanced German, and conversational French.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Irina Elena Haivas invests in
Stages Irina Elena Haivas invests in
Countries Irina Elena Haivas invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $11M–$31M
- Series B
- $44M–$56M
Investment Focus
Industry
- Health Care 4 (40%)
- Software 3 (30%)
- Biotechnology 3 (30%)
- Artificial Intelligence 3 (30%)
- Internet 2 (20%)
Stage
- Series A 6 (60%)
- Series B 2 (20%)
- Seed 1 (10%)
- Series C 1 (10%)
Country
- United Kingdom 6 (60%)
- Estonia 1 (10%)
- Germany 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Healx
|
Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io. | $47M / Series C / Aug 01, 2024 | |
LabGenius
|
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics. | $44.5M / Series B / May 21, 2024 | |
NFTPort
|
NFTPort provides one-stop and developer-friendly NFT infrastructure and APIs for developers such as Stripe for NFTs. The company was founded by Kaspar Peterson and Johannes Tammekänd, and is headquartered in Tallinn, Estonia. | $26M / Series A / Jun 15, 2022 | |
Y42
|
Y42 is a low-code data platform that allows users to integrate, transform, and visualize their data that enable them to integrate multiple data sources and build scalable data infrastructure without coding. The company's all-in-one data platform runs on top the data warehouse and helps users to load hundreds of data sources, clean, connect,and share data.Founded in 2020 by Hung Dang, Y42 is headquartered in Berlin, Germany. | $31M / Series A / Oct 25, 2021 | |
|
LabGenius
|
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics. | $15M / Series A / Oct 30, 2020 | |
Qatalog
|
Qatalog eliminates your work chaos. No more constant pings, no more trivial meetings, and no more scouring for the latest doc.Our work hub connects the tools of modern collaboration — wikis, project management, team chat, and more — and lets you use them in concert with each other.It connects people and teams in the same way, so they can be insync when they're not in the same place. It’s the new way of work.Qatalog is a Salesforce Ventures company and a 2021 Gartner Cool Vendor. | $26M / Series A / Oct 13, 2020 | |
|
Healx
|
Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io. | $56M / Series B / Oct 16, 2019 | |
Kheiron
|
At Kheiron, we are going where only a few have gone before; seeking a new understanding of cancer and how to detect it using artificial intelligence and human insight.We’ve made significant breakthroughs with our breast cancer screening product Mia but this is just the beginning of our journey. Ultimately we want to radically improve the outcomesfor cancer patients by pioneering a new era of, what we call, precision radiology.While this all sounds very serious and it is, we believe in having fun along the way. Karaoke is our favourite sport. We also have an incredible crew from more than twenty different countries and offices in London, Budapest, Amsterdam and San Francisco. Giving every woman a better fighting chance against cancer. | $22M / Series A / Sep 23, 2019 | |
Daye
|
Daye has set out to build a new brand for female health products “designed with women in mind.” The startup’s first product is a newly developed tampon that uses CBD to help tackle period cramps (or dysmenorrhea) as an alternative to traditional painkillers (CBD is the extract derived from the flower of the industrial hemp plant, a legal relativeto marijuana). | $5.5M / Seed / May 10, 2019 | |
Accurx
|
Accurx is where conversations happen with and about patients. Through one, easy-to-use platform, we help everyone involved in a patient’s care to communicate and collaborate.Whether you’re a patient or a healthcare professional, Accurx lets you connect seamlessly with the people you need to. You can use Accurx to: send SMS messages and medicalsurveys, provide appointment reminders and referrals, hold video consultations, and manage virtual wards, outpatient clinics and follow-up pathways.Accurx is used by 98% of GP practices and in 50% of NHS trusts. | $11.5M / Series A / Feb 24, 2019 |
Co-Investors
About Creative Destruction Lab
Creative Destruction Lab (CDL) is a no-fee/no-equity organization that delivers an objectives-based mentoring program for massively scalable, pre-seed stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success. Founded in 2012 byProfessor Ajay Agrawal at the University of Toronto’s Rotman School of Management, the program has expanded to thirteen sites across seven countries: Seattle, Oxford, Paris, Atlanta, Estonia, Wisconsin, Vancouver, Calgary, Montreal, Berlin, Melbourne and Halifax.
Creative Destruction Lab Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anthony K. Tjan
Fellow
|
|||
Daniel Mulet Lind
Associate Director, Quantum Machine Learning
|
|||
Dennis Bennie
Founding Partner and Associate
|
|||
Dennis Kavelman
Founding Partner and Associate
|
|||
Frederic Bastien
Fellow
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Irina Elena Haivas invest in?
Irina Elena Haivas invests primarily in Health Care, Software and Biotechnology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Irina Elena Haivas's check size?
Irina Elena Haivas typically joins rounds of $11M–$31M at Series A and $44M–$56M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Irina Elena Haivas participates in.
How do I contact Irina Elena Haivas?
Public channels for Irina Elena Haivas include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Irina Elena Haivas last invest?
The most recent investment recorded for Irina Elena Haivas closed in Aug 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
